Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (March 2019)
23 slides from Adma Biologics's investor presentation, Mar 18, 2019
Slide 1: ADMA Biologics: Groundbreaking Immunotechnology, One Connection at a Time
WWW-ADMABIOLOGICS.COM ADMA ADMA Biologics Groundbreaking Immunotechnology, One Connection at a Time March 2019 Nasdaq: ADMA
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘This presentaton contains “forwaré-ookng statements” pusuant to thesafeharbor provisions ofthe Pvate Secures Liigaton Reform Act of 1995 about ADMA Biologics, Inc wer “our or the “Compan, incuing, without Emitation, statements thet may predict forecast inate, or imply fut
Slide 3: Who We Are
WHO WE ARE ADMA Biologics is a vertically integrated commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the immune- compromised and other patients at risk for infection, It is our devotion to these underserved populations t
Slide 4: Corporate Highlights
CORPORATE HIGHLIGHTS el VERTICALLY-INTEGRATED COMMERCIAL BIOPHARMACEUTICAL COMPANY. Operates an FDA-approved 400,000L capacity plasma therapeutics manufacturing facility with potential for expansion Products acquired: Nabi-HB® (Hepatitis B IG, Human) and BIVIGAM® (IVIG, Human) Control all aspects of
Slide 5: Near & Mid-Term Objectives
NT NEAR & MID-TERM OBJECTIVES * Manufacturing * FDA approval received for BIVIGAM® Prior Appro * Rapid response submitted January 4, 2019 to FDA for BI f (CRL)- Subsequently, FDA has provided information requests regarding the CRL resubmission and the Company has responded * RI-002 BLA Resubmitted t
Slide 6: Experienced Management Team and Board of Directors
EXPERIENCED MANAGEMENT TEAM AND BOARD OF DIRECTORS NAME SELECTED CURRENT OF PAST AFFILIATIONS ‘Adam Grossman Founder, President, CEO & Director lial g G Medimmune Genesis Genes Ec eset an KPMG BioSNI aE a @ shay, nes © oa <a QRHNG — tesmenscw oe & Gees = NIM ANowrtor aoe Baxter (SPPTA ION cee FR Pha
Slide 7: Blood & Plasma Composition
BLOOD & PLASMA COMPOSITION \ Sa Blood Contains: Plasma, Red Cells, White Cells and Platelets Plasma Contains: Protein and Water Plasma Proteins Contain Many Therapeutic Benefits + IVIG is made from a key therapeutic protein in plasma: IgG + IgG = naturally occurring polyclonal antibodies against bac
Slide 8: ADMA Is One of a Handful of Vertically Integrated Plasma Products Manufacturers
ADMA IS ONE OF A HANDFUL OF VERTICALLY INTEGRATED PLASMA PRODUCTS AND SPECIALTY IMMUNE GLOBULIN MANUFACTURERS IN THE U.S. + Track record of receiving FDA approval for plasma collection centers + ~400,000L annual capacity plasma fractionation and purification plant operating in FDA compliance + ADMA
Slide 9: Market Opportunities
Market Opportunities Commercial Overview, RI-002 t Pipeline Nasdaq: ADMA
Slide 10: Growth Drivers: Plasma Market Is Sizeable
I GROWTH DRIVERS: PLASMA MARKET IS SIZEABLE GEaey IMMUNE GLOBULIN (IG) (e.g., BIVIGAM®) is a pooled plasma product from healthy plasma donors, containing a range of polyclonal antibodies against common pathogens IG IS USED TO 1G WIDELY TREAT A WIDE MARKETED VARIETY OF IN THE U.S. DISORDERS 7 compani
Slide 11: Commercial Products: Established Brands in an Expanding IG Market
COMMERCIAL PRODUCTS: ESTABLISHED BRANDS IN AN EXPANDING IG MARKET BIVIGAM® a (immune Globulin intravenous Human) " FDA-Approved protection against serious infections <Bivicam + Human intravenous immune globulin, 10% liquid Hare), 10% gid Indicated for the treatment of patients with PIDD Contains a w
Slide 12: IG Is Widely Used and Reimbursed
IG IS WIDELY USED AND REIMBURSED FDA-Approved Uses* Additional Reimbursed Evidence-Based Uses Primary immunodeficiency (PIDD) ‘Acquired red cell aplasia Multiple myeloma Rasmussen's syndrome Multifocal motor neuropathy Bone marrow transplantation Myasthenia gravis nes transplant from liver y Neonata
Slide 13: PIDD Is a Significant Market Opportunity for ADMA
PIDD IS A SIGNIFICANT MARKET OPPORTUNITY FOR ADMA RI-002 Potential Target Popul: ~250,000 PIDD PATIENTS in the US. Class Est. Incidence (U.S.) Target Population 2 Population Numbers Common Variableimmune 1 in 25,000to 1 in 50,000 2,000to 5,000 patients ~50% are treated with 1G Deficiency (CVID) (7,0
Slide 14: ADMA Is an Advocate for the PIDD Patient
ADMA IS AN ADVOCATE FOR THE PIDD PATIENT GEaey + Type and severity of immune deficiency + Age + Impaired pulmonary function = Bronchiectasis ~ Asthma ; of respondents of PIDD patients reported —History of respiratory infection/environmental conditions reported having asthma they suffer from chronic
Slide 15: Leading a New Paradigm in Immunotechnology: RI-002
LEADING A NEW PARADIGM IN IMMUNOTECHNOLOGY: RI-002 GEaey Our lead product candidate, RI-002, is being developed for the treatment of PIDD Completed a pivotal Phase Ill clinical study, met primary endpoint and reported positive secondary endpoint(s) RI-002 is the basis for ADMA’s patented methodology
Slide 16: een RA)
een RA) 18
Slide 17: ADMA Pipeline
ADMA PIPELINE Potential Follow-On Indication Populations for RI-002 After initial FDA approval for PIDD, ADMA intends to seek to expand the label for RI-002 to address these populations’ unmet medical needs regarding RSV infection management + HSCT/Bone Marrow Transplant — ~25,000 procedures/year pe
Slide 18: Expanding Product Portfolio with Additional Specialty IG Products
By leveraging ADMA's IP, know-how and expertise, we may seek to expand our product portfolio with additional specialty IG products by building upon our core competency of identifying high-titer plasma donors and plasma products manufacturing expertise
Slide 19: ADMA Products, Pipeline and Ongoing R&D
ADMA PRODUCTS, PIPELINE AND ONGOING R&D Product / Candidate BIVIGAM® R&D Activity / Other Information Pediatric Indication / Pre- | Phase dinical | 1 Phase | Phase BLA FDA Approved / u i —_| Submitted Marketed ‘Awaiting FDA action on en Serco Human, Immunoglobulin intravenous _| Manufacturing Optimi
Slide 20: Milestones & Financial Highlights
Milestones & Financial Highlights Nasdaq: ADMA
Slide 21: Milestones
MILESTONES Recently Completed Future & Ongoing Objectives 2019 + Completed a $72.5M debt financing facility with Perceptive Advisors « + Successfully closed-out April 2018 FDA inspection . + Inspection classification status improved to VAI + Submitted RI-002 CRL response and resubmitted BLA for revi
Slide 22: Financial Information
FINANCIAL INFORMATION ant Summary: 12/31/18 Results Cash, cash equivalents $228M Total assets $88.9M Total liabilities $69.1M Total stockholders’ equity $198M Revenue $17.0M Common stock outstanding 46.4M Fully diluted common stock outstanding 51.2M * Subsequent Event: Perceptive Advisors Debt Refin
Slide 23: Plasma Collection and Vertical Integration
PLASMA COLLECTION VERTICAL INTEGRATION ABILITY TO SUPPLY 4 PORTION OF THE INTERNAL NEEDS AND SELL TO 3) E & HYPERIMMUNE BILITIES TIES CONTRACT MANUFACTURING & TESTING CURRENT CONTRACT FOR HYPERIMMUNE GLOBULIN MONOCLONAL FACILITY FULL QC LABORATORY